Investigating The Propellant Pathways Leading To a Sustainable Future of MDIs
Download the Article Description: The article discusses the transition to low GWP propellants in the respiratory drug delivery sector as current high-GWP variants are phased out. The leading propellant options for the next generation of low GWP MDIs ( metered dose inhalers) are HFA 152a and HFO 1234ze from the hydro-fluoroolefin family. The article highlights […]
Propellant Aerosols & Transition to Low GWP pMDIs
Understand how the properties of propellant aerosols guide the transition to low global warming potential pMDIs.
Nanopharm: cGMP Drug Development in OINDP
Nanopharm expands with cGMP facilities for advanced drug development in OINDP. Specializing in biologics characterization and particle engineering.
Primary Crystallization’s Influence on Fluticasone DPIs
Discover the impact of crystallization on mechanical properties & secondary processing of Fluticasone Propionate in dry powder inhaler formulations.
A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant
Discover Nanopharm’s breakthrough in dry-powder HPV vaccines. Learn how GLA enhances aerodynamic performance for effective inhalation delivery of the antigen.
Albuterol & Low GWP Propellants: Deposition Prediction
Explore predictions of regional deposition and systemic exposure of Albuterol Sulfate with low global warming potential propellants in pMDIs.
Raman Spectroscopy for Nasal Suspension Drugs
Explore a systematic approach in developing Morphologically-Directed Raman Spectroscopy for characterizing nasal suspension drug products.
Fundamental properties of propellant aerosols can guide transition to low global warming potential pMDIs: size, velocity and surface charge
Discover Nanopharm’s groundbreaking research on Low GWP propellants in pMDIs. Learn how they revolutionize drug delivery and the role of valve and actuators.
Nanopharm: Valve Types & Container Systems in pMDIs with Salmeterol
Explore Nanopharm’s study on the impact of valve types and container closure systems in pMDIs. Focus on formulations with Salmeterol Xinafoate and how they perform under stressed conditions.
Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
Understand how particle size impacts inhalation drug delivery and the role of dry powder inhalers (DPIs) in treating respiratory diseases.
